This is an open label Phase II study in elderly patients (65y or older) with early breast
cancer who are candidate for adjuvant chemotherapy. A scheme with liposomal doxorubicin
(Caelyx) and cyclophosphamide (endoxan) will be used. The aim is to study the cardiac effects
of liposomal doxorubicin with new non-invasive techniques, ie strain rate imaging, classical
echocardiography, and special blood tests measuring troponin I and BNP.